Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mitraphylline is a pentacyclic oxindole alkaloid primarily isolated from the inner bark of Uncaria tomentosa (Cat's Claw), a plant native to South America. It has demonstrated significant antiproliferative and cytotoxic activities in various human cancer cell lines, including Ewing's sarcoma (MHH-ES-1) and breast cancer (MT-3), by inhibiting cell growth in a dose-dependent manner. Research suggests it may also possess anti-inflammatory properties by modulating cytokine production, specifically through the inhibition of pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), and interleukin-1 beta (IL-1B). While it is a key bioactive component in traditional herbal preparations, mitraphylline is primarily studied as a research compound for its potential oncological and anti-inflammatory therapeutic applications.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on mitraphylline.